Real life effectiveness of omalizumab in severe allergic asthma, does the IgE level matter? A Bradford experience

S. Jain, D. Saralaya, K. Regan, L. Walker (Bradford, United Kingdom)

Source: Annual Congress 2013 –Treatment of asthma
Session: Treatment of asthma
Session type: Thematic Poster Session
Number: 918
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Jain, D. Saralaya, K. Regan, L. Walker (Bradford, United Kingdom). Real life effectiveness of omalizumab in severe allergic asthma, does the IgE level matter? A Bradford experience. Eur Respir J 2013; 42: Suppl. 57, 918

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Real life experience of omalizumab on selected children with severe allergic asthma
Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma
Year: 2016


Real-world outcomes in patients receiving omalizumab for allergic asthma in India: Analysis by baseline IgE level
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013


Effectiveness of omalizumab in Greek patients with severe allergic asthma (SAA): The SMILE study
Source: International Congress 2016 – Asthma points to ponder
Year: 2016

Risk factors of incomplete asthma control in asthmatic patients with allergic rhinitis
Source: Annual Congress 2013 –Asthma
Year: 2013


One year following a real life experience of omalizumab for moderate to severe persistent allergic asthma in Malta
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013


A pilot study for markers which can reflect asthmatic activity before and after reduction of inhaled corticosteroids
Source: Annual Congress 2013 –Assessment of airway inflammation by exhaled gases
Year: 2013

Efficacy of omalizumab in allergic asthma by asthma severity and eosinophilic status
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015


Total and free IgE in evolution of severe asthma after omalizumab treatment
Source: International Congress 2016 – Asthma management
Year: 2016


The ’real-life’ long-term efficacy of omalizumab in severe persistent IgE-mediated allergic asthma in Malta
Source: International Congress 2016 – Asthma management
Year: 2016


Allergic versus non allergic asthma: What makes the difference?
Source: International Congress 2015 – Clincal aspects of asthma: monitoring and mechanisms
Year: 2015

Pharmacogenetics in severity of bronchial hyperresponsiveness in asthma
Source: Annual Congress 2013 –Genetic factors in airway development and disease
Year: 2013

Comparison of clinical features of severe persistent asthma and refractory asthma
Source: Annual Congress 2013 –Phenotyping asthma: clinical severity, comorbid conditions response to treatment?
Year: 2013


Prevalence of refractory asthma in population with severe asthma
Source: International Congress 2016 – Phenotyping and monitoring airway diseases
Year: 2016


Effects of allergic rhinitis on self-management and quality of life in adult patients with asthma
Source: International Congress 2014 – From individual patient interactions to models of care: the nursing perspective
Year: 2014

Inhalation technique education and its impact in asthma and COPD
Source: International Congress 2015 – Is asthma always an easy disease to diagnose and manage?
Year: 2015

A "real life" study on height in prebupertal asthmatic children receiving inhaled steroids
Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma
Year: 2016

Safety of sputum monitoring in a severe asthma population - The Manchester severe asthma team experience
Source: International Congress 2016 – Assessing lower airway inflammation with different tools
Year: 2016


Patients with allergic and eosinophilic asthma in the German severe asthma registry
Source: International Congress 2015 – Asthma and lung immunology
Year: 2015


The real world burden of illness in uncontrolled asthma with elevated eosinophils
Source: International Congress 2016 – Asthma: treatment, disease control, and quality of life
Year: 2016


Clinical outcomes in non-eosinophilic versus eosinophilic asthma after 12 months specialist management
Source: International Congress 2015 – Non-exhaled biomarkers in the assessment of airways disease
Year: 2015